About us
Protecting our tomorrow
A firm focus on vaccines stands at the core of everything we do.
READ MORE
At a glance
Our Leadership Team
Governance
Business Ethics
Sustainability
What we do
From R&D to manufacturing
We are focused on the research, development and manufacturing of innovative life-saving vaccines
READ MORE
Products
Pipeline
INVESTORS
Investors
We are committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more
Annual Report 2023
News
Events & Presentations
Financials
Stock information
Analysts
Annual General Meeting
Shareholder Portal
FAQ
Careers
Careers
We offer a challenging international working environment in which job satisfaction and personal growth have a high priority.
READ MORE
Working With Us
Job Openings
Our Employees

Mpox media information

PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.

April 2, 2024

Bavarian Nordic announced the commercial launch of JYNNEOS^® (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) in the U.S.

JYNNEOS is the first FDA-approved mpox vaccine and was made available for individuals at risk during the 2022-2023 mpox outbreak by the U.S. government.

JYNNEOS is now recommended for routine use in individuals 18 years and older with certain risk factors, and is now available nationwide for wholesaler and distribution partners to make it available for individuals at risk at local pharmacies and physician offices in addition to public health clinics.

Protecting our tomorrow

From R&D to manufacturing

Investors

Careers

Mpox media information